Hosted on MSN5d
Denali Starts Dosing in Phase II Parkinson's Disease StudyDenali Therapeutics Inc. DNLI initiated dosing in a global mid-stage study, BEACON, on BIIB122 (DNL151). BIIB122, an ...
SOUTH SAN FRANCISCO, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced initiation of dosing in a global Phase 2a clinical study, BEACON, of the ...
Hosted on MSN11mon
Does Denali Therapeutics Inc. (DNLI) Have the Potential to Rally 123.38% as Wall Street Analysts Expect?Denali Therapeutics Inc. (DNLI) closed the last trading session at $21.17, gaining 17% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets ...
Check the time stamp on this data. Updated AI-Generated Signals for Denali Therapeutics Inc. (DNLI) available here: DNLI.
Denali Therapeutics (DNLI) announced initiation of dosing in a global Phase 2a clinical study, BEACON, of the investigational drug leucine-rich ...
Denali Therapeutics shares are moving lower in Thursday's after-hours session after the company announced that its Phase 2 study of oditrasertib was discontinued. Biogen (NASDAQ: BIIB) reported ...
View Denali Therapeutics Inc. (DNLI) current and estimated P/E ratio data provided by Seeking Alpha.
Denali Therapeutics (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Denali Therapeutics Inc. DNLI initiated dosing in a global mid-stage study, BEACON, on BIIB122 (DNL151). BIIB122, an investigational drug leucine-rich repeat kinase 2 (LRRK2) inhibitor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback